AI Chatroom: AI + Digital Health | USA
DLA Piper presents AI ChatRoom, a captivating series of conversational videos that helps businesses understand the rapidly evolving landscape of Artificial Intelligence (AI) laws and regulations. In this video, Danny Tobey, partner, has an in-depth discussion with Keo Shaw, of counsel, and Kristi Kung, partner, about how AI is revolutionising the digital health industry, the potential of AI in delivering improved patient care, and what health agencies are doing to keep up with these rapidly evolving technologies.
The Current State of AI in Healthcare
The experts note that AI is increasingly being used in healthcare, particularly in behavioural health treatments like virtual reality simulations for phobias. However, the development of fully autonomous AI devices has been slower, due in part to regulatory hurdles. While agencies like the FDA are open to innovation and are even using AI themselves, the rapid pace of technological change poses a constant challenge for regulation.
Patient Readiness and Ethical Considerations
While patients may not be ready for fully autonomous healthcare, they are generally comfortable with clinicians using AI to inform treatment decisions. This highlights the need for medical education to focus on teaching doctors how to critically evaluate AI tools, similar to how they assess clinical studies. The discussion also touches on the importance of clear labelling for AI devices, especially when they are used directly by patients.
Challenges and Opportunities in AI Adoption
Healthcare systems are often unprepared for the comprehensive adoption of AI, lacking resources and clear policies for governance, monitoring, and testing. Collaboration between regulatory agencies and industry is crucial to ensure that AI is used safely and effectively. The experts also emphasise the importance of clinical validation in the same environment where the tool will be deployed to identify and address potential biases and errors.
The Future of AI in Healthcare
The experts envision a future where AI enables precision medicine, with personalised treatments tailored to individual patients. Regulatory agencies are already thinking about how to manage this future, but challenges remain around clinical validation for individualised therapies. The use of AI in clinical trials is another promising area, with the potential to optimise participant selection, improve trial diversity, and enhance both speed and quality of data analysis.
Conclusion
The discussion paints an optimistic picture of the future of AI in healthcare, highlighting the potential for significant medical advances in the next decade. However, it also underscores the importance of addressing regulatory challenges, ensuring ethical and transparent use of AI, and preparing healthcare systems for the widespread adoption of this transformative technology.